【摘要】 目的探讨肿瘤转移抑制基因编码蛋白KAI1/CD82和能动性相关蛋白-1(MRP-1/CD9)在膀胱移行细胞癌中的表达及临床意义。方法采用免疫组织化学SP法观察52例膀胱癌石蜡标本中和KAI1/CD82和MRP-1/CD9的表达情况,结合临床资料进行分析。结果膀胱癌组织中KAI1/CD82和MRP-1/CD9的阳性表达率分别为50%和61.5%。KAI1/CD82和MRP-1/CD9阳性表达率在复发肿瘤中均随病理分级升高而下降(P<0.05),但与临床分期无关(P>0.05)。KAI1/CD82和MRP-1/CD9和的阳性表达率有显著相关性(r=0.316,P<0.05)。结论KAI1/CD82和MRP-1/CD9的表达可能是判断膀胱癌生物学行为的重要指标。更多还原

【Abstract】 [Objective] To investigate expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of the bladder (TCCB) and its clinical significance. [Methods] Immunohistochemistry was used to detect KAI1/CD82 and MRP-1/CD9 protein expression in 52 TCCB specimens. Correlations of the expression of KAI1/CD82 and MRP-1/CD9 to clinicopathological factors were statistically analyzed. [Results] The positive rates of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of the bladder were 50% and 61.5%, respectively. MRP-1/CD9 and KAI1/CD82 expression was significantly associated with the pathological grade of TCCB (P <0.05), but no correlation was found between MRP-1/CD9 or KAI1/CD82 expression and clinical stage of TCCB(P >0.05). Furthermore, MRP-1/CD9 and KAI1/CD82 were expressed at lower level in recurrent TCCB samples than that of non-recurrent samples(P <0.05). Meanwhile, the correlation between KAI1/CD82 expression and MRP-1/CD9 expression was statistically significant(r=0.316, P <0.05). [Conclusions] KAI1/CD82 and MRP-1/CD9 may be important prognostic indicators and potentially useful for assessing the biological behaviors of transitional cell carcinoma of the bladder.更多还原